Decoding the Key to Biotech Global Expansion: Genfleet Pharmaceuticals’ Evolving BD Strategy and Consistent Success

VCBeat has learned that GenFleet Therapeutics, a clinical-stage innovative drug development company with a global footprint, has entered into a strategic licensing agreement with Verastem Oncology (Nasdaq: VSTM), a Nasdaq-listed company, for three preclinical innovative drug pipelines, including RAS pathway-targeted therapies.

Leveraging both parties’ strengths in RAS pathway research, this licensing agreement will enable comprehensive collaboration across the entire pipeline, from early-stage R&D to clinical development, regulatory approval, and commercialization. Verastem will serve as the exclusive partner, securing global development and commercialization rights for three of GenFleet Therapeutics’ drug candidates outside the Greater China region.The total value of this collaboration exceeds US$600 million, further strengthening GenFleet Therapeutics’ long-term cash reserves.

Since last year, the record for outbound licensing deals of China’s innovative drugs has been continuously broken, with collaborative projects extending from the New Drug Application (NDA) stage back to earlier development phases, and total transaction values reaching new highs. This trend demonstrates the foresight and efficiency of leading biotech companies in expanding into overseas markets, as well as the recognition of domestic biotechs by international firms. It also highlights the growing originality of Chinese products going global, underscoring the development potential of Chinese enterprises and the vast opportunities for international collaboration.

In the recent landscape of licensing-out deals, successful cases of antibody-based therapies, such as ADCs and bispecific antibodies, are increasingly common. Compared to antibody drugs that have achieved breakthroughs through downstream process engineering, small-molecule drugs—which face greater challenges in early-stage project initiation and R&D—exhibit lower activity levels. In particular, small-molecule “out-licensing” transactions driven by product pipelines account for an even smaller share of global new drug deals.

In this transaction between GenFleet Therapeutics and Verastem, three anti-tumor therapies led by RAS pathway-targeting small molecules not only demonstrate the expertise and experience of both companies in this research field, but also indicate that innovative therapies based on mature technologies hold promising commercial prospects in the long-term, high-growth industry sector.

In fact, after years of system integration and commercial exploration, GenFleet has established an increasingly mature collaboration framework tailored to its R&D products at different stages. To date, GenFleet has forged diversified partnerships with domestic and international listed companies, including Innovent Biologics, Merck, SELLAS, BioLineRx, and Junshi Biosciences. Its successful commercial collaborations—spanning out-licensing, cooperative clinical development, and combination therapy exploration—are not confined to any single fixed model.

Dr. Lü Qiang, Founder and Chairman of GenFleet Therapeuticsstated,The fundamental differentiation of GenFleet’s commercialization partnerships lies in aligning with market trends—driven by its product pipeline and guided by clinical needs, rather than relying solely on an engineered technology platform. By forming complementary advantages with partners, GenFleet achieves synchronized optimization and allocation of resources for both parties, thereby enhancing operational efficiency.GenFleet has established a highly diverse product portfolio by developing innovative therapies in various formats targeting different mechanisms, and by exploring indications based on molecular characteristics and frontier research trends within each therapeutic area. Furthermore, the company has implemented differentiated development models tailored to the market prospects and risk-return profiles of individual projects, thereby achieving innovation in its external collaboration strategies.

Regarding the collaboration with Verastem,Dr. Qiang Lvstated that this marks the Company’s first comprehensive commercial collaboration for a product in the early development stage, and also serves as a market validation of GenFleet Therapeutics’ integrated capabilities spanning from R&D to commercialization.“In addition to our shared and complementary technical strengths, our partners’ understanding of overseas markets, their R&D expertise in specialized fields, and their clinical resources will provide greater impetus for us to initiate projects tailored to global market demands. Meanwhile, sustained licensing revenue will also provide GenFleet with more robust cash flow, thereby better facilitating the clinical development of collaborative projects both domestically and internationally.”

Dr. John Chen, Head of Strategic Development at GenFleet Therapeuticsstated,Comprehensive communication spanning R&D, manufacturing, and clinical development runs through the entire course of project collaboration, reflecting GenFleet’s consistent approach to business communication.Regarding overseas clinical development, he acknowledged its high costs and uncertainties, but noted that international studies are also a key approach to enhancing product value. By collaborating with distinguished partners, GenFleet Therapeutics can better showcase the highlights of its products to overseas markets and authoritative principal investigators (PIs), thereby improving their prospects for global clinical development and commercialization.

Current Commercial Collaboration Projects of GenFleet Therapeutics (Source: GenFleet Therapeutics)

GenFleet’s first out-licensing partner was Innovent Biologics. In 2021, the two companies closed the largest-ever deal for a locally developed IND-stage product concerning GFH925, which was developed by GenFleet. Currently, the registrational clinical studies of GFH925 as a monotherapy have been completed in China. Innovent will lead the commercialization of GFH925 in China, leveraging its experienced commercial team and nationwide distribution channels, while GenFleet will be responsible for overseas clinical studies and take the lead in manufacturing and supply for both clinical and commercial purposes.

Furthermore, GenFleet Therapeutics has entered into a European multicenter clinical study and drug supply agreement with the multinational pharmaceutical company Merck to jointly evaluate GFH925 in combination with cetuximab, an approved EGFR monoclonal antibody, as a first-line treatment for patients with non-small cell lung cancer (NSCLC). Compared with similar therapies offered by many multinational pharmaceutical companies, this study targets first-line treatment and maintains a leading position in international development progress. It represents not only a new exploration of indications for GFH925 but also an effective pathway for the company to pursue overseas approval and market launch through combination therapy.

Dr. Fanwei ChenHe stated that he “customized” the most suitable business cooperation model for each BD project within two years.Rather than blindly exploring possibilities, he chose to focus on risk factors at each development milestone, thereby enhancing both the R&D efficiency and success rate of the project, while also reinforcing both parties’ commitment to advancing the project on a mutually beneficial basis.The synergy between “hard power” and “soft power” ensures the sustainability of GenFleet Therapeutics’ international development.

Looking back on the journey, Dr. Lü Qiang believes that the company anchored its startup strategy in “global-first” R&D, focusing primarily on targets and indications without prior clinical validation. Starting with traditional small-molecule and antibody therapy development, the company has since built an autonomous, integrated R&D system recognized by both domestic and international markets. He stated, “The difficulty of early-stage R&D is often proportional to future commercial potential; this was the forward-looking R&D-plus-commercialization project initiation strategy we established at inception. Our system now covers the entire value chain, including early research, clinical development, translation, manufacturing, and business development (BD). Through every setback and victory, we have continuously refined our operations and grown, accumulating momentum for future industrialization.”

In the current climate of capital market contraction, both investors and enterprises are anticipating commercial returns as projects reach certain stages of development. How to coordinate system and cultural construction in a more intensive and efficient manner constitutes a significant test for management’s ability to allocate resources in alignment with market changes.Dr. Qiang LuIt is essential to act in accordance with the times, live within one’s means, and distinguish between “braking items” and “full-throttle items.” Meanwhile, maintaining and enhancing the integrity of the integrated R&D system, as well as fostering the development of internal and external collaboration networks, remain the foundation and key to supporting product lines and continuously launching innovative therapies.

GenFleet Therapeutics Financing History (Source: GenFleet Therapeutics) 

The “protracted war” of an integrated R&D system requires stable cash flow support; to date, GenFleet Therapeutics has disclosed cumulative financing across multiple rounds exceeding RMB 1 billion.

While financial support from investors is undoubtedly important, companies also need to develop the ability to generate “self-sustaining revenue,” which tests their capacity for external communication and for quantifying the value of the company and its projects.After identifying potential partners for the project, the company needs to articulate and quantify its core value propositions, translating them into a clear and communicable “language” to facilitate collaboration.In traditional discussions on “going global,” these “values” are often directly defined as project pipelines; however, a company’s comprehensive capabilities in project initiation, early-stage R&D, clinical trial design, and process development and manufacturing are also indispensable for securing partnerships. GenFleet Therapeutics’ diverse commercial collaborations serve as a compelling testament to this.

Next, GenFleet Therapeutics will fully advance the commercial manufacturing of the GFH925 project, enhancing the company’s future revenue outlook. Meanwhile, it will continue to promote its pipeline-driven sustainable development model, closely aligning with investor expectations and generating greater substantial returns.